Cornerstone gets US Bankruptcy Court okay to acquire rights to antibiotic factive from Oscient

Cornerstone Therapeutics Inc., specialty pharmaceutical company focused on acquiring, developing and commercializing significant products primarily for the respiratory and related markets, announced that it has received the approval of the United States Bankruptcy Court for the District of Massachusetts for its acquisition of the commercial rights to the antibiotic Factive (gemifloxacin mesylate) in North America and certain countries in Europe from Oscient Pharmaceuticals Corporation and expects to promptly close the transaction. 

Comments

Popular posts from this blog

GOP Senator says it's hard to fund $14 billion children's health care program — then advocates for $1 trillion tax cut

Trump wants more mental health care; Alabama says it's trying